These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Gottlieb DJ, Luisetti M, Stone PJ, Allegra L, Cantey-Kiser JM, Grassi C, Snider GL. Am J Respir Crit Care Med; 2000 Dec; 162(6):2069-72. PubMed ID: 11112116 [Abstract] [Full Text] [Related]
6. Effect of diet on urinary excretion of desmosine and hydroxylysyl pyridinoline. Stone PJ, Lucey EC, Snider GL, Franzblau C. Am J Respir Crit Care Med; 1994 Jan; 149(1):174-7. PubMed ID: 8111578 [Abstract] [Full Text] [Related]
12. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, Turino GM. Eur Respir J; 2008 Nov; 32(5):1146-57. PubMed ID: 18978133 [Abstract] [Full Text] [Related]
13. Alpha-1-antitrypsin and other proteinase inhibitors. Miravitlles M. Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503 [Abstract] [Full Text] [Related]
14. An enzyme-linked immunosorbent assay (ELISA) for the quantitation of urinary desmosine. Watanabe T, Ishimori K, Verplanke AJ, Matsuki H, Kasuga H. Tokai J Exp Clin Med; 1989 Sep; 14(4):347-56. PubMed ID: 2487974 [Abstract] [Full Text] [Related]
18. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Lieberman J. Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705 [Abstract] [Full Text] [Related]
19. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antritrypsin deficiency-related COPD. Fregonese L, Ferrari F, Fumagalli M, Luisetti M, Stolk J, Iadarola P. COPD; 2011 Oct; 8(5):329-33. PubMed ID: 21793711 [Abstract] [Full Text] [Related]